upgrad teva neutral underweight rais pt
although realiti eros copaxon lost us longer perceiv
downsid risk significantli greater major gener compani
primarili function retail market landscap character
modest pace price eros larg favor dynam surround ajovi
migrain prophylaxi though still doubt regard ebitda
ultim trough dynam cite view remov risk
dramat eros ebitda go forward vein current ebitda
multipl unlik contract significantli
look like ajovi head signific success initi took
cautiou approach given ajovi first mover advantag
aimovig enjoy avail via auto-injector pen recal aimovig
lilli emgal avail once-monthli self-inject via auto-injector wherea
ajovi avail via pre-fil syring given per month everi
week said ajovi outpac emgal term weekli retail prescript
rx rx share among three anti-cgrp agent week end
ajovi retail rx around account weekli anti-cgrp rx per
iqvia compar rx rx share around respect
emgal teva note around ajovi rx quarterli regimen
surmis dynam key reason ajovi emerg anti-
cgrp product three consecut inject per quarterli regimen
non-start base weekli vial volum assum steady-st gross-to-net
spread estim ajovi net sale annual around
though like good bit higher given aggress effort
drive new starts/access larger take-away signific contribut ajovi
austedo render eros copaxon less problemat
still major challeng gener conced worst appear
separ piec publish note took closer look
rhetor manag team dynam improv would
take mean price stabl go forward given power buyer
consortium coupl larg number oversea competitor dosag
form capabl everi bit sophist major dynam
also dilut valu underli gener pipelin much valu
extract given file ultim entrant may
believ teva point real visibl modest steady-
state eros gener busi
risk includ copaxon competit gener price risk
teva leader gener neurology-focus drug
price close januari
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
past point signific multipl contract major risk much
believ signific multipl contract ebitda peak low-teen
real risk given follow item eros copaxon mg/ml due
entri gener octob uncertainti surround trajectori
gener busi given confluenc power buyer consortium signific
grow number oversea compani make high-qual gener technic
challeng one essenti dilut valu given anda pipelin high
degre caution part surround new brand product particularli ajovi context
highli competit landscap though multipl contract come pass toward
end function overal macro-environ rather deterior
underli teva busi given grow evid improv condit
gener point modest eros price oppos stabil notabl
evid ajovi gain signific traction render eros copaxon less
problemat longer perceiv dramat downsid risk teva share put anoth way
longer perceiv downsid risk greater teva gener peer
quit readi conclud visibl lt ebitda stabil
believ ebitda declin significantli part latest think driven
combin look like soft land copaxon steadi moder pace
eros grow contribut austedo huntington diseas chorea tardiv
dyskinesia td ajovi layer backdrop aggress cost
cut program shave expens base versu
regard copaxon recent week prescript rx data per iqvia
mg/ml product account rx volum compar around end
end teva continu play defens copaxon aggress
rebat limit competit environ certainli win strategi term
moder pace volum eros expens net realiz price extent
time see addit gener entrant hand pend file
inevit volum eros combin price eros said grow
contribut austedo ajovi render dynam less problemat replac high-
margin asset high-margin brand
muse austedo regard austedo check key opinion leader along
commentari teva neurocrin regard ingrezza point td landscap
accommod agent though feedback physician whole
somewhat favor ingrezza complex titrat once-daili dose box warn
relat suicid two caveat noteworthi evid
rel complex titrat schedul titrat mg weekli interv maximum daili
dose mg could somewhat advantag allow greater dose flexibl
box warn specif huntington popul physician manag td
recogn note sale austedo
product first full year market
ajovi admittedli surpris us previous taken cautiou approach
product given first-mov advantag notabl avail
auto-injector pen present turn three consecut self-inject given everi
week place market teva note around ajovi rx written
quarterli dose regimen beyond panacea migrain space
vein patient certainli fail given anti-cgrp agent respond
anoth one heard anecdot patient perceiv greater inject site
page
pain associ pen pre-fil syring base feedback check
key opinion leader refer note highlight migrain specialist panel
annual piper jaffray healthcar confer detail bottom line
context treatment set respons variou therapi individu
idiosyncrat surpris migrain prophylaxi landscap accommod multipl
anti-cgrp agent simpli thought ajovi would oper competit disadvantag
due present turn case
week end prescript written ajovi account
anti-cgrp volum volum share amgen aimovig lilli emgal
respect per iqvia note averag number vial per rx bear
mind monthli dose regimen entail use singl vial month quarterli
regimen entail use vial shot administ consecut rx monthli
quarterli base number vial dispens assum spread
gross net sale net sale ajovi annual around caveat
gross-to-net spread cite steady-st figur teva allud
steady-st said surmis
good bit wider given signific activ part teva drive new start signific
subsid patient out-of-pocket cost
ajovi prescript vial
page
account fact prescript ajovi written quarterli dose vial monthli dose vial teva previous mention
written quarterli dose per iqvia number vial per roughli
page
sale salestot anti-cgrp monoclon antibodi mab sequenti total ajovi sequenti teva retail ajovi per per per per ajovi exhibit
anti-cgrp prescript market share
page
aimovig ajovi teva emgal weeklyvolumeweeklyvolumeweeklyvolumedatetrx growthshar trx growthshar trx growthshar word key gener name epipen forteo recal teva ab-rat
gener version epipen epinephrin auto-injector gain approv august teva began
shipment limit quantiti late full launch dose mg
mg well underway seventh week data per iqvia rx gener total
account total epipen volum rx author gener total
recent week data account volum brand account
nearli volum recal amneal kaleo distribut non-substitut
epinephrin auto-injector product known adrenaclick auvi-q respect adrenaclick
rx account overal market volum auvi-q rx account around
volum lastli note symjepi pre-fil epinephrin syring distribut adami
admp launch earlier month though surmis aggress seek
maintain posit market domin note file
substitut product knowledg translat potenti signific contribut
teva product extend period
major potenti contributor gener busi noteworthi teva
gener version forteo teriparatid inject product approv osteoporosi
postmenopaus women osteoporosi men high risk fractur glucocorticoid-
induc osteoporosi men post-menopaus women manag continu guid
potenti launch recal teva lilli settl patent litig given
teva first-to-fil statu compani day gener exclus sale
forteo annual
though forteo product clearli technic challeng term bring substitut
gener market recombin parathyroid hormon competit landscap somewhat
fluid note radiu health cover tymlo abaloparatid inject
parathyroid hormon analog launch may annual list price around
compar annual list price around forteo report net sale
also note cover file nda product known
decemb via use forteo refer list drug rld
though teva forteo gener could certainli signific contributor evolv natur
competit landscap could limit longer term impact product
new pt base price-to-earnings unchang ep estim
versu prior ep estim discount unchang one year
new pt translat ebitda multipl though
realiti continu eros copaxon lost us evid worst appear
term eros gener segment grow contribut ajovi
austedo point limit risk major eros ebitda though would yet conclud
visibl ebitda trough high regard chang model rais
estim ajovi base favor launch metric date
valuat conclus support dcf analysi refer exhibit
detail factor steady-st eros gener low-singl digit annual
ajovi sale exceed austedo sale approach dcf
also reflect copaxon sale fall continu signific
presenc teva translat valu per share solidli mid-teen
page
note prior estim comparison may applic due pjc updat report line item
consensu estim
compani report factset research pjc estim
page
million except per america market non-cor consensu incom expens net share consensu exhibit
ev equiti valu per share calcul use termin growth rate top wacc left assumpt
base dilut share outstand reflect full convers mandatori convert prefer share
compani report pjc estim
page
free america segmentgener america segment segment gener segment market segmentgener market segment good develop gener incom depreci oper provis incom oper depreci capit increas net work cash valu cash valuationenterpris valu growth cash cash termin valu per teva share dilut share valu per teva teva quarterli annual incom statement
million except ep
sale
sell gener administr
incom loss tax
cog product revenu
expens total revenu
sell gener administr
sell gener administr
teva alter revenu report methodolog result histor may reflect pjc estim
proprietari piper jaffray januari
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
